180 Life Sciences Corp. (ATNF)
Market Cap | 1.55M |
Revenue (ttm) | n/a |
Net Income (ttm) | -16.24M |
Shares Out | 941.59K |
EPS (ttm) | -29.19 |
PE Ratio | n/a |
Forward PE | 6.08 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 17,022 |
Open | 1.530 |
Previous Close | 1.500 |
Day's Range | 1.481 - 1.650 |
52-Week Range | 1.310 - 21.470 |
Beta | 0.45 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Aug 12, 2024 |
About ATNF
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of... [Read more]
Financial Performance
Financial StatementsNews
![](https://cdn.snapi.dev/images/v1/s/f/press7-2506445.jpg)
180 Life Sciences Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
PALO ALTO, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that it received notice from the Nasdaq Listing Qual...
![](https://cdn.snapi.dev/images/v1/5/h/press15-2324182.jpg)
180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
PALO ALTO, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that the Company received a letter on March 13, 202...
![](https://cdn.snapi.dev/images/v1/i/c/press9-2293082.jpg)
180 Life Sciences Corp. Announces 1-For 19 Reverse Stock Split as Part of Nasdaq Compliance Plan
PALO ALTO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that it will conduct a reverse stock split of its ou...
![](https://cdn.snapi.dev/images/v1/s/d/press20-2181910.jpg)
180 Life Sciences Engages Financial Advisor to Explore Strategic Alternatives
PALO ALTO, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced it has engaged A.G.P./Alliance Global Partners as fi...
![](https://cdn.snapi.dev/images/v1/k/m/press19-2173873.jpg)
180 Life Sciences Announces Review of Strategic Alternatives
PALO ALTO, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that its Board of Directors has initiated a process ...
![](https://cdn.snapi.dev/images/v1/5/i/press11-2022498.jpg)
180 Life Sciences Corp. Announces Closing of $3 Million Public Offering
PALO ALTO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced the closing o...
![](https://cdn.snapi.dev/images/v1/s/x/press17-2017142.jpg)
180 Life Sciences Corp. Announces Pricing of $3 Million Public Offering
PALO ALTO, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced the pricing o...
![](https://cdn.snapi.dev/images/v1/g/f/press10-2009727.jpg)
180 Life Sciences Announces an Agreement for a Clinical Pharmacology Study Testing a New Formulation of CBD for Enhanced Oral Uptake
PALO ALTO, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that an agreement has been reached with Prof. Avi Do...
![](https://cdn.snapi.dev/images/v1/7/s/press6-1831457.jpg)
180 Life Sciences Corp. Announces Closing of $3 Million Registered Direct Offering and Concurrent Private Placement
PALO ALTO, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced the closing ...
![](https://cdn.snapi.dev/images/v1/z/h/press16-1827219.jpg)
180 Life Sciences Corp. Announces $3 Million Registered Direct Offering and Concurrent Private Placement
Priced At-The-Market Under Nasdaq Rules Priced At-The-Market Under Nasdaq Rules
![](https://cdn.snapi.dev/images/v1/o/u/press18-1772030.jpg)
180 Life Sciences Announces Presentation at the Gordon Conference
PALO ALTO, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that Professor Jagdeep Nanchahal has been selected t...
![](https://cdn.snapi.dev/images/v1/o/t/press7-1767168.jpg)
180 Life Sciences Announces Allowance of Claims for a US Patent for Dupuytren's Disease Treatment and Application
PALO ALTO, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that the United States Patent and Trademark Office (...
![](https://cdn.snapi.dev/images/v1/5/o/press10-1766173.jpg)
180 Life Sciences Provides Update Regarding Anti-TNF Frozen Shoulder Trial
PALO ALTO, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced closure to recruitment of men and women across Engla...
![](https://cdn.snapi.dev/images/v1/u/t/press17-1722281.jpg)
180 Life Sciences Announces Publication of a Review on the Treatments for Early Stage Dupuytren's Disease
PALO ALTO, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced the publication of a review entitled ‘Treatments for...
![](https://cdn.snapi.dev/images/v1/r/k/press10-1703134.jpg)
Newman Ferrara LLP Investigating Officers and Directors of 180 Life Sciences Corp. (ATNF)
NEW YORK--(BUSINESS WIRE)--Newman Ferrara LLP announced today that it has an ongoing investigation into actions taken by officers and directors of KBL Merger Corp. IV (“KBL”), a special purpose acqu...
![](https://cdn.snapi.dev/images/v1/p/d/press8-1694639.jpg)
180 Life Sciences Announces Publication of a Review on the Biological Basis of Dupuytren's Disease
PALO ALTO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced the publication of a review entitled ‘Dupuytren's di...
![](https://cdn.snapi.dev/images/v1/r/m/press19-1689912.jpg)
180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Shareholders
PALO ALTO, Calif., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Dear Fellow Shareholder,
![](https://cdn.snapi.dev/images/v1/w/z/press16-1686215.jpg)
180 Life Sciences Corp. Announces Closing of $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
PALO ALTO, Calif., Dec. 23, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced the closing o...
![](https://cdn.snapi.dev/images/v1/a/d/press2-1682593.jpg)
180 Life Sciences Corp. Announces $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
PALO ALTO, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced that it has ...
![](https://cdn.snapi.dev/images/v1/8/y/press20-1678479.jpg)
180 Life Sciences Corp. Announces 1-for 20 Reverse Stock Split as Part of Nasdaq Compliance Plan
PALO ALTO, Calif., Dec. 16, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that it will effect a one-for-20 reverse stock split...
![](https://cdn.snapi.dev/images/v1/q/4/press15-1657669.jpg)
180 Life Sciences Provides Update on Progress To Seek Medicines and Healthcare Products Regulatory Agency Marketing Authorization for Anti-TNF Treatment of Early Stage Dupuytren's Contracture
PALO ALTO, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that the Company and its regulatory consultants from...
![](https://cdn.snapi.dev/images/v1/x/p/press11-1645981.jpg)
180 Life Sciences to Participate in A.G.P.'s Virtual Biotech Conference to be Held November 30 – December 1, 2022
PALO ALTO, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of...
![](https://cdn.snapi.dev/images/v1/i/a/press8-1638236.jpg)
CORRECTION: Adalimumab Found To Be A Likely Cost-Effective Treatment for Early-Stage Dupuytren's Disease
PALO ALTO, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) -- A correction has been issued for the release disseminated under the same headline on Thursday, November 15th by 180 Life Sciences Corp. An embedded...
![](https://cdn.snapi.dev/images/v1/t/b/press2-1557632.jpg)
180 Life Sciences Issues Letter to Stockholders
PALO ALTO, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company today released the following...
![](https://cdn.snapi.dev/images/v1/t/k/press9-1513774.jpg)
180 Life Sciences with the University of Oxford Announce the Enrollment of the First Patient in a Trial of Anti-TNF for People with Early-Stage Frozen Shoulder
PALO ALTO, Calif., Aug. 22, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company announced that the first pati...